HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
Business Wire•17/11/2026•11:45 ET
0
Key Highlights
- ➤Natera (NTRA) named Best in Class for Cancer, Screening & Early Detection
- ➤Signatera MRD test recognized for cancer-care impact at HLTH 2026
- ➤Awards attracted more than 1,300 submissions globally
- ➤Signatera used by the majority of U.S. oncologists, company says
Expert Statements
Solomon Moshkevich, Chief Executive Officer, Natera
“Signatera is transforming the practice of medicine by enabling earlier, more targeted interventions for those patients who need them, and by helping spare others from unnecessary treatment and its side effects.”
Solomon Moshkevich, Chief Executive Officer, Natera
“We are honored by this recognition from HLTH 2026, and we are grateful to the patients, clinicians, researchers, and partners who make our work possible.”
HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
Recognition is part of the Digital Health Hub Foundation Digital Health & AI Awards, which received more than 1,300 submissions globally
Get started
Create a free account to read the full story.
